National Vision Holdings, Inc. (EYE): Price and Financial Metrics

National Vision Holdings, Inc. (EYE)

Today's Latest Price: $26.50 USD

2.01 (-7.05%)

Updated May 28 6:55pm

Add EYE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 33 in Specialty Retailers

See all "A" rated Strong Buy stocks

EYE Stock Summary

  • EYE's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 220.77 -- higher than 85.57% of US-listed equities with positive expected earnings growth.
  • National Vision Holdings Inc's stock had its IPO on October 26, 2017, making it an older stock than just 7.82% of US equities in our set.
  • With a price/earnings ratio of 84.72, National Vision Holdings Inc P/E ratio is greater than that of about 93.08% of stocks in our set with positive earnings.
  • If you're looking for stocks that are quantitatively similar to National Vision Holdings Inc, a group of peers worth examining would be SPXC, CRAI, EEFT, SAIA, and CCB.
  • Visit EYE's SEC page to see the company's official filings. To visit the company's web site, go to
EYE Daily Price Range
EYE 52-Week Price Range

EYE Stock Price Chart More Charts

EYE Price/Volume Stats

Current price $26.50 52-week high $39.88
Prev. close $28.51 52-week low $11.70
Day low $26.36 Volume 965,400
Day high $29.04 Avg. volume 1,010,612
50-day MA $23.06 Dividend yield N/A
200-day MA $27.98 Market Cap 2.13B

National Vision Holdings, Inc. (EYE) Company Bio

National Vision Holdings, Inc. operates as a retailer and manufacturer of eyeglasses and value retailer of contact lenses. The company operates through Owned and Host, and Legacy segments. It offers eyeglasses and contact lenses, as well as optometric services. The company was founded in 1990 and is based in Duluth, Georgia.

EYE Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

Below please find a table outlining a discounted cash flow forecast for EYE, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that National Vision Holdings Inc ranked in the 92th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 2862.17% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of National Vision Holdings Inc, consider:

  • Its compound free cash flow growth rate, as measured over the past 2.53 years, is 1.53% -- higher than 95.01% of stocks in our DCF forecasting set.
  • National Vision Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
  • The weighted average cost of capital for the company is 8. This value is greater than 68.56% stocks in the Consumer Cyclical sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of National Vision Holdings Inc? See MLR, ODP, WINA, MDCA, and BH.

EYE Latest News Stream

Event/TimeNews Detail
Loading, please wait...

EYE Latest Social Stream

Loading social stream, please wait...

View Full EYE Social Stream

Latest EYE News From Around the Web

Below are the latest news stories about National Vision Holdings Inc that investors may wish to consider to help them evaluate EYE as an investment opportunity.

QIAGEN (QGEN) Reports Preliminary Revenue Results for Q1

Investors remain optimistic with QIAGEN's (QGEN) first-quarter 2020 preliminary revenue results, which is likely to benefit from increased testing demand for coronavirus infection.

Yahoo | April 15, 2020

Bio-Rad Rides on International Expansion Amid Cost Concerns

Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.

Yahoo | April 9, 2020

Medtronic (MDT) Demonstrates Global Growth Amid Cost Concerns

Medtronic's (MDT) international Diabetes business registers solid growth on the continued adoption of MiniMed 670G in overseas markets.

Yahoo | April 8, 2020

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

Investors continue to be optimistic about Thermo Fisher (TMO) on its strong segmental growth in the fourth quarter of 2019.

Yahoo | April 7, 2020

Product Launches Aid Hill-Rom Amid Project Timing Issues

Hill-Rom (HRC) plans to roll out five-six new products each year through 2022.

Yahoo | April 7, 2020

Read More 'EYE' Stories Here

EYE Price Returns

1-mo -7.60%
3-mo -23.89%
6-mo -12.25%
1-year -3.64%
3-year N/A
5-year N/A
YTD -18.29%
2019 15.12%
2018 -30.63%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8576 seconds.